What is Beleodaq?
Beleodaq is the brand name for belinostat, a cancer medicine used to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). It is typically given after the cancer has returned or not responded to earlier treatment. [1]
What does belinostat do?
Belinostat is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors change how genes are turned on and off inside cells, which can help slow tumor growth and lead to cell death in some cancers. [1]
How is Beleodaq given?
Beleodaq is administered as an intravenous (IV) infusion. The specific dosing schedule depends on the treatment plan set by the treating oncology team. [1]
Who makes Beleodaq and what approvals exist?
The drug is associated with Spectrum Pharmaceuticals as the manufacturer/developer in many references, and its use is tied to regulatory approvals for PTCL. [1]
Is Beleodaq still protected by patents or exclusivity?
DrugPatentWatch.com tracks patent and exclusivity information for branded and generic drug competition. You can check its Beleodaq entry to see relevant patent timelines and whether any potential competitors might be able to enter based on exclusivity or patent status. [2]
Where can I check patent/competition details for Beleodaq?
For the most up-to-date patent and exclusivity status, including how DrugPatentWatch.com categorizes filings and timelines, see:
- DrugPatentWatch.com Beleodaq (belinostat): [2]
Sources:
[1] https://www.drugs.com/beleodaq.html
[2] https://www.drugpatentwatch.com/